Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 10/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.76 |
| ▸ | KDR | P35968 | 4/20 | 0.73 |
| ▸ | FLT3 | P36888 | 4/20 | 0.73 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.73 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.73 |
| ▸ | CSF1R | P07333 | 2/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.70 |
| ▸ | SRC | P12931 | 2/20 | 0.70 |
| ▸ | FLT1 | P17948 | 2/20 | 0.70 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | FLT4 | P35916 | 2/20 | 0.70 |
| ▸ | ABL1 | P00519 | 2/20 | 0.70 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | GMNN | O75496 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416658 | 1.00 | RET (1.00) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL2126784 | 1.00 | RET (1.00) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL19978 | 0.84 | RET (1.00) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL13081086 | 0.84 | RET (1.00) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL5203211 | 0.84 | PDPK1 (1.00) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL31726696 | 0.84 | RET (0.76) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL5478517 | 0.84 | PDPK1 (1.00) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL19979 | 0.84 | RET (1.00) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL5475962 | 0.84 | PDGFRB (0.81) | RETPDGFRBKDRFLT3ALK | |
| SCHEMBL5475963 | 0.84 | PDGFRB (0.81) | RETPDGFRBKDRFLT3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722388-A1 | PREDICTION OF AN OUTCOME OF A SUBJECT SUFFERING FROM ACUTE MYOLOID LEUKEMIA | Koninklijke Philips N.V. (NL) | 2026-04-08 | — | — | EP | claimed |
| EP-4572781-A2 | SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT | The United States of America, as Represented By the Secretary, Department of Health and Human Services (US) | 2025-06-25 | — | — | EP | claimed |
| CN-115298180-B | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 日本理化学研究所 | 2025-06-10 | — | — | CN | claimed |
| WO-2024040132-A2 | SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2024-02-22 | — | — | WO | claimed |
| EP-3468602-B1 | FLT3 RECEPTOR INHIBITOR AT LOW DOSAGE FOR THE TREATMENT OF NEUROPATHIC PAIN | INST NAT SANTE RECH MED (FR) | 2023-02-22 | — | — | EP | claimed |
| EP-4121430-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | Flash Therapeuttics, LLC (US) | 2023-01-25 | — | — | EP | claimed |
| US-20220387362-A1 | COMPOSITIONS COMPRISING A DHODH INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | RHIZEN PHARMACEUTICALS AG (CH) | 2022-12-08 | — | — | US | claimed |
| CN-115298180-A | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 富雷旭医疗有限责任公司 | 2022-11-04 | — | — | CN | claimed |
| EP-4048251-A1 | COMPOSITIONS COMPRISING A DHODH INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | Rhizen Pharmaceuticals AG (CH) | 2022-08-31 | — | — | EP | claimed |
| CN-114828842-A | Composition comprising DHODH inhibitor for the treatment of acute myeloid leukemia | 理森制药股份公司 | 2022-07-29 | — | — | CN | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124314-A1 | ANTl-5T4 ANTIGEN BINDING DOMAINS, ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | SALUBRIS BIOTHERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12600704-B2 | Substituted 1,2,4-triazoles and methods of use | STINGINN LLC (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4722388-A1 | PREDICTION OF AN OUTCOME OF A SUBJECT SUFFERING FROM ACUTE MYOLOID LEUKEMIA | Koninklijke Philips N.V. (NL) | 2026-04-08 | — | — | EP | disclosed |
| EP-3969438-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | Stingthera, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3969452-A1 | BENZO[B][1,8]NAPHTHYRIDINE ACETIC ACID DERIVATIVES AND METHODS OF USE | Stingthera, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11273142-B2 | Treatment for tumors driven by metabolic dysfunction | SYNDEVRX, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| WO-2022042676-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273142-B2 | Treatment for tumors driven by metabolic dysfunction | PCK2, GOT2, PC | RET 1418/4885PDGFRB 3894/4885KDR 2247/4885 |
| US-12600704-B2 | Substituted 1,2,4-triazoles and methods of use | STING1, IRF3, MAVS | RET 2518/4885PDGFRB 1089/4885KDR 3119/4885 |
| US-20220387362-A1 | COMPOSITIONS COMPRISING A DHODH INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | DHODH, FLT3, IDH3A | RET 274/4885PDGFRB 1171/4885KDR 505/4885 |
| US-20260124314-A1 | ANTl-5T4 ANTIGEN BINDING DOMAINS, ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CD2, CD2BP2, ABCC4 | RET 1243/4885PDGFRB 1577/4885KDR 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.